MCRB — Seres Therapeutics Share News
0.000.00%
Last trade - 00:00- $20.78m
- $5.18m
- $0.79m
Seres to sell bacterial infection drug to Nestle Health for an undisclosed sum (updated)
Seres to sell bacterial infection drug to Nestle Health
Seres Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Seres Therapeutics Q1 EPS USD -0.27
Seres Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Foreign automakers eager for Chinese partners at Beijing auto show
Foreign automakers eager for Chinese partners at Beijing auto show
Battle for 'tech luxury' in China as EVs get smarter - and cheaper
Brief: Seres Therapeutics Announces Completion Of Patient Enrollment For SER-155 Phase 1B Cohort 2 Clinical Trial In Allogenic HSCT
U.S. RESEARCH ROUNDUP-Arrivent Biopharma, Ferguson, Target
Seres Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Seres Therapeutics FY EPS USD -0.89
Seres Therapeutics Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: Seres Therapeutics Announces Appointment of Marella Thorell as Chief Financial Officer and Retirement of David Arkowitz
U.S. STOCKS ON THE MOVE-ResMed, Revvity, Acuity Brands
U.S. STOCKS ON THE MOVE-Albemarle, Illumina, Eversource Energy
U.S. STOCKS ON THE MOVE-CrowdStrike, Precision BioSciences, Tilray Brands
Brief: Seres Therapeutics Announces US FDA Fast Track Designation For SER-155
Seres Therapeutics rises on FDA's 'fast track' tag for bacterial infection drug